All In Biotech

Drug Trial Radar · NCT07876856

A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 1/2 Study to Evaluate AHB-137 Injection Followed by TVAX-008 Injection in Participants With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogs

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Sep 22, 2028

Study completion Jun 20, 2029

Sponsor

Lead sponsor
Ausper Biopharma Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).

Conditions

  • Chronic Hepatitis B

Interventions

  • AHB-137Drug

    AHB-137 will be administered per 1 week.

  • PlaceboDrug

    Placebo will be used per 4 weeks.

  • TVAX-008Drug

    TVAV-008 will be administered per 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety indicators of Phase 1Time frame: Up to 72 weeks.
  2. HBV DNA < LLOQ and HBsAg < LOD, 0.05 IU/mL with or without HBsAb 24 weeks after discontinuation of all CHBs of Phase 2Time frame: Up to 72 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.